Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015979 | 0.94 | KDR (0.45) | KDRFGFR3FLT3 | |
| SCHEMBL3029778 | 0.84 | FGFR3 (0.50) | KDRFGFR3FLT3 | |
| SCHEMBL3031154 | 0.81 | FYN (0.52) | KDRFGFR3 | |
| SCHEMBL836396 | 0.81 | FGFR1 (0.43) | FGFR3DYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL3020724 | 0.81 | KDR (0.51) | KDRFGFR3 | |
| SCHEMBL3025677 | 0.80 | KDR (0.48) | KDRFGFR3GABRG2GABRB3GABRA3 | |
| SCHEMBL3031157 | 0.79 | GABRG2 (0.52) | KDRFGFR3FLT3GABRG2GABRB3 | |
| SCHEMBL3029705 | 0.78 | KDR (0.65) | KDRFGFR3FLT3GABRG2GABRB3 | |
| SCHEMBL3322220 | 0.77 | FLT3 (0.66) | KDRFGFR3FLT3 | |
| SCHEMBL3022097 | 0.77 | KDR (0.62) | KDRFGFR3FLT3GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | claimed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | KDR 372/4885FGFR3 32/4885DYRK3 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.